

Colorectal Cancer: Pathway to Survival

PRODUCT DISCLOSURE

Reflecting standard oncology practice, which often requires uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration, this educational activity includes information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this activity—colorectal cancer) of all products and devices under discussion. This information, as of the time of printing, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care.

Generic Name	Brand Name	FDA Approved for the Treatment of Colorectal Cancer	FDA Approved for Other Indications	Investigational for the Treatment of Colorectal Cancer
Albuterol	Various		✓	
Amifostine	Ethylol		✓	
Bevacizumab	Avastin	✓		
Capecitabine	Xeloda	✓	✓	
Celecoxib	Celebrex		✓	✓
Cetuximab	Erbix	✓	✓	
Clindamycin (topical)	Cleocin		✓	
Diphenhydramine	Benadryl		✓	
Doxycycline	Various		✓	
Epinephrine	Various		✓	
5-Fluorouracil (5-FU)	Adrucil	✓	✓	
Glutamine	Various		✓	
Hydrocortisone topical	Various		✓	
Irinotecan	Camptosar	✓		
Leucovorin (folinic acid)	Wellcovorin	✓	✓	
Loperamide	Imodium		✓	
Minocycline	Various		✓	
Oxaliplatin	Eloxatin	✓		
Panitumumab	Vectibix	✓		
Pimecrolimus	Elidel		✓	
Xaliproden			✓	*

Adapted from *Drug Facts and Comparisons*. St Louis, Mo: Facts & Comparisons; 2006.

Agents may be approved for use in combination.

*Investigational for preventing peripheral neuropathy associated with oxaliplatin.